
J&J shells out $1.75bn for viral therapies developer Alios
Executive Summary
Johnson & Johnson is buying private infectious disease therapeutics developer Alios BioPharma Inc. for $1.75bn in cash.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com